A biotech founder in Cambridge or San Francisco can now generate their drug's first human data in a

At a biopharma we work with, there's a CRO that runs a particular assay the company orders many

When we talk to customers about what an agent should be allowed to do in their workspace, the most common

Somewhere in the world right now, a scientist is taking a photograph of a paper lab notebook, uploading the image

Biotech outcomes are binary and milestone-gated, and the math on that doesn't really have a gradient: if

When we started building Kaleidoscope, we didn’t set out to build an end-to-end platform. Our initial observation

In the last few weeks, three separate prospects reached out to us in what looked like sudden bursts of interest.

A question we hear often from biopharma leadership and investors: "With AI improving this fast, do we really need

There's a harmful posture across biopharma that is hampering meaningful progress: a belief that certain categories of work

Most onboarding journeys hit an early inflection point: a moment when it becomes clear whether the software will actually stick.